| Application no. and date | 18842846.0 (espacenet) (Federated) (European Patent Register), 20181221 | | Patent/reg. no. and date | DK/EP 3727423, 20240522 | | Publication date | 20201028 | | Priority no. and date | US 201762609489 P, 20171222 | | EP pub. no. and date |
EP 3727423 20201028 | | Effective date | | | Applicant/owner | Novartis AG, Lichtstrasse 35
4056 Basel, CH | | Applicant ref. no. | V477533DK00 | | Inventor | GOLDFINE, Allison, c/o Novartis Institutes for Biomedical Research,
Inc. 250 Massachusetts Avenue
Cambridge, Massachusetts 02139, US,
YI, Byungdoo Alexander, c/o Novartis Institutes for Biomedical Research,
Inc. 250 Massachusetts Avenue
Cambridge, Massachusetts 02139, US | | Representative | Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S | | Opponent | | | IPC Class | A61K 38/18 (2006.01) , A61K 45/06 (2006.01) , A61P 3/04 (2006.01) , A61P 3/06 (2006.01) , A61P 5/50 (2006.01) , A61P 9/10 (2006.01) , A61P 9/12 (2006.01) | | Title | Behandling af metaboliske lidelser med FGF21-varianter | | Int. application no. | IB2018060538 | | Int. publication no. | WO2019123427 | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
